TheStreet downgraded shares of Astrazeneca PLC (NYSE:AZN) to a hold rating in a research note released on Friday.

Several other research firms have also recently commented on AZN. Beaufort Securities reissued a hold rating on shares of Astrazeneca PLC in a research note on Thursday, August 11th. Citigroup Inc. reissued a buy rating on shares of Astrazeneca PLC in a research note on Saturday, June 25th. Jefferies Group raised shares of Astrazeneca PLC from a hold rating to a buy rating in a research note on Monday, September 12th. Shore Capital reaffirmed a hold rating on shares of Astrazeneca PLC in a research note on Wednesday, July 20th. Finally, Argus began coverage on shares of Astrazeneca PLC in a research note on Tuesday, July 12th. They issued a hold rating on the stock. Three investment analysts have rated the stock with a sell rating, nine have issued a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of Hold and a consensus price target of $37.56.

Astrazeneca PLC (NYSE:AZN) traded up 1.0046% on Friday, hitting $30.8973. The company’s stock had a trading volume of 6,624,223 shares. Astrazeneca PLC has a 1-year low of $26.97 and a 1-year high of $35.04. The company has a 50 day moving average price of $32.87 and a 200-day moving average price of $30.88. The company has a market capitalization of $78.17 billion, a P/E ratio of 35.3112 and a beta of 0.75.

Astrazeneca PLC (NYSE:AZN) last released its quarterly earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.07. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The business had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.56 billion. During the same period in the prior year, the firm earned $1.21 earnings per share. Astrazeneca PLC’s revenue was down 4.0% compared to the same quarter last year. On average, equities analysts forecast that Astrazeneca PLC will post $2.97 earnings per share for the current fiscal year.

A number of institutional investors have recently added to or reduced their stakes in AZN. Forester Capital Management LTD boosted its position in Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares in the last quarter. First Interstate Bank boosted its position in Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock worth $118,000 after buying an additional 2,730 shares in the last quarter. Synovus Financial Corp boosted its position in Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock worth $132,000 after buying an additional 1,000 shares in the last quarter. Fifth Third Bancorp boosted its position in Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares in the last quarter. Finally, Integrated Investment Consultants LLC boosted its position in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares in the last quarter. Institutional investors and hedge funds own 11.46% of the company’s stock.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

5 Day Chart for NYSE:AZN

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.